Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | FGB | P02675 | 1/20 | 0.41 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.41 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4905688 | 0.81 | KDM4E (0.71) | KDM4EL3MBTL1MAPTLMNAALDH1A1 | |
| SCHEMBL4899087 | 0.81 | KDM4E (0.71) | KDM4EL3MBTL1MAPTLMNAALDH1A1 | |
| SCHEMBL6651894 | 0.81 | KDM4E (0.71) | KDM4EL3MBTL1MAPTLMNAALDH1A1 | |
| SCHEMBL6920287 | 0.81 | KDM4E (0.71) | KDM4EL3MBTL1MAPTLMNAALDH1A1 | |
| SCHEMBL9499461 | 0.77 | KDM4E (0.69) | KDM4EL3MBTL1MAPTLMNAALDH1A1 | |
| SCHEMBL4906765 | 0.77 | KDM4E (0.65) | KDM4EL3MBTL1MAPTLMNAALDH1A1 | |
| SCHEMBL11669860 | 0.75 | KDM4E (0.75) | KDM4EL3MBTL1MAPTLMNAALDH1A1 | |
| SCHEMBL11671087 | 0.75 | L3MBTL1 (0.68) | KDM4EL3MBTL1MAPTLMNAALDH1A1 | |
| SCHEMBL5599158 | 0.75 | KDM4E (0.61) | KDM4EL3MBTL1MAPTLMNAALDH1A1 | |
| SCHEMBL4902046 | 0.74 | KDM4E (0.60) | KDM4EL3MBTL1MAPTLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1363635-B1 | SUBSTITUTED 8-ARYLQUINOLINE PHOSPHODIESTERASE-4 INHIBITORS | MERCK & CO INC (US) | 2009-04-15 | — | — | EP | disclosed |
| US-6740666-B2 | FOR THERAPY OF ASTHMA, CHRONIC BRONCHITIS, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, EOSINOPHILIC GRANULOMA, PSORIASIS; SEPTIC SHOCK, ULCERATIVE COLITIS, CROHN'S DISEASE, REPERFUSION INJURY OF THE MYOCARDIUM AND BRAIN, INFLAMMATION | MERCK & CO., INC. | 2004-05-25 | — | — | US | disclosed |
| EP-1363635-A1 | SUBSTITUTED 8-ARYLQUINOLINE PHOSPHODIESTERASE-4 INHIBITORS | Merck & Co., Inc. (US) | 2003-11-26 | — | — | EP | disclosed |
| US-20020143032-A1 | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2002-10-03 | — | — | US | disclosed |
| EP-1244628-A1 | SUBSTITUTED 8-ARYLQUINOLINE PHOSPHODIESTERASE-4 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 2002-10-02 | — | — | EP | disclosed |
| WO-2002069970-A1 | SUBSTITUTED 8-ARYLQUINOLINE PHOSPHODIESTERASE-4 INHIBITORS | MERCK & CO., INC. (US) | 2002-09-12 | — | — | WO | disclosed |
| US-20020103226-A1 | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2002-08-01 | — | — | US | disclosed |
| US-6410563-B1 | RESPIRATORY SYSTEM DISORDERS; ANTIARTHRITIC AGENTS | MERCK FROSST CANADA & CO. (CA) | 2002-06-25 | — | — | US | disclosed |
| WO-2001046151-A1 | SUBSTITUTED 8-ARYLQUINOLINE PHOSPHODIESTERASE-4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103226-A1 | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors | PDE4A, PDE4B, PDE4C | KDM4E 63/4885L3MBTL1 3284/4885MAPT 4352/4885 |
| US-20020143032-A1 | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors | PDE4A, PDE4B, PDE12 | KDM4E 367/4885L3MBTL1 4187/4885MAPT 4413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.